Table 1

Baseline characteristics of incident and prevalent users prescribed Step-2 maintenance therapy

Baseline characteristicsLTRA (n*=85)ICS (n*=433)
Age,Embedded Image11.3 ± 3.99.7±4.2
Female, n (%)42 (49.4)186 (43.0)
Ethnicity, n (%)
 Caucasian68 (80.0)261 (60.3)
 Black8 (9.4)64 (14.8)
 Other9 (10.6)108 (24.9)
Income, M±IQR45 684 (19 929)40 187 (19 527)
Weight status, n (%)
 BMI ≤80th percentile44 (51.8)218 (50.4)
 BMI >80th percentile41 (48.2)215 (49.6)
Exposure to cigarette smoke, n (%)41 (48.2)121 (27.9)
% Predicted FEV1,Embedded Image99±12.898±14.1
Asthma phenotype, n (%)
 Episodic/Seasonal37 (43.5)174 (40.2)
 Persistent48 (56.5)259 (59.8)
Global assessment of severity, n (%)
 Mild84 (98.8)340 (78.5)
 Moderate-severe1 (1.2)93 (21.5)
Exacerbations for asthma in previous year, n (%)
Acute care visits
 015 (28.6)64 (14.78)
 118 (20.0)99 (22.86)
 222 (31.4)104 (24.01)
 ≥330 (20.0)142 (32.8)
Hospitalisations
 083 (97.7)368 (85.0)
 ≥12 (2.3)65 (15.0)
Oral corticosteroids
 079 (94.3)298 (68.8)
 ≥16 (5.7)135 (31.2)
Asthma-related comorbidities, n (%)†
 None55 (64.7)202 (46.7)
 Atopy‡26 (30.6)214 (49.4)
 Upper/Lower respiratory conditions§7 (8.2)43 (9.9)
Triggers, n (%)†
 Viral54 (63.5)310 (71.6)
 Allergic38 (44.7)191 (44.1)
 Effort53 (62.4)189 (42.7)
 Temperature7 (8.2)66 (14.9)
  • *Number of person-trials.

  • †Categories are not mutually exclusive.

  • ‡Atopic conditions comprise eczema, allergic rhinitis, conjunctivitis and food allergies.

  • §Chronic upper or lower respiratory tract comorbidities include a history of recurrent otitis, sinusitis, pneumonia, gastro-oesophageal reflux disease, obstructive sleep apnoea, bronchopulmonary aspergillosis, vocal cord dysfunction or dysphagia.

  • BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.